Processa Pharmaceuticals, Inc. Gain (Loss) on Sale of Assets and Asset Impairment Charges
Processa Pharmaceuticals, Inc. (PCSA) reported Gain (Loss) on Sale of Assets and Asset Impairment Charges of -$62.55 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. gain (loss) on sale of assets and asset impairment charges for fiscal 2015 was -$62.55K.
| Period end | Gain (Loss) on Sale of Assets and Asset Impairment Charges 12 month |
|---|---|
| 2015-12-31 | -$62.55K 10-K · filed 2017-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |